Trials / Completed
CompletedNCT06285240
Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)
A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Safety, Tolerability, and Pharmacokinetics of MK-1167 Administered to Patients With Alzheimer's Disease Receiving Stable Donepezil Treatment
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 50 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to assess the safety and efficacy of MK-1167 administered to participants with Alzheimer's Disease (AD) receiving stable Donepezil treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK-1167 | 1 mg and 5 mg oral capsules |
| DRUG | Donepezil | 10 mg oral tablets |
| DRUG | Placebo | MK-1167 matching placebo administered oral capsules |
Timeline
- Start date
- 2024-03-28
- Primary completion
- 2024-09-23
- Completion
- 2024-09-23
- First posted
- 2024-02-29
- Last updated
- 2025-10-14
- Results posted
- 2025-10-14
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06285240. Inclusion in this directory is not an endorsement.